76 related articles for article (PubMed ID: 23326955)
21. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
Kozielewicz D; Halota W; Dybowska D
Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
[TBL] [Abstract][Full Text] [Related]
22. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
Vachon ML; Dieterich DT
Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
[TBL] [Abstract][Full Text] [Related]
23. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
[TBL] [Abstract][Full Text] [Related]
24. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
[TBL] [Abstract][Full Text] [Related]
25. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection.
Wyles DL
Top HIV Med; 2010; 18(4):132-6. PubMed ID: 21107012
[TBL] [Abstract][Full Text] [Related]
26. Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.
Chevaliez S
Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S46-51. PubMed ID: 22248694
[TBL] [Abstract][Full Text] [Related]
27. [Outline of HCV treatment].
Akuta N; Kumada H
Nihon Rinsho; 2015 Feb; 73(2):243-8. PubMed ID: 25764678
[TBL] [Abstract][Full Text] [Related]
28. Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials.
Aghemo A; Degasperi E; Colombo M
Dig Liver Dis; 2013 Jan; 45(1):1-7. PubMed ID: 22695478
[TBL] [Abstract][Full Text] [Related]
29. Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV.
Patel N; Veve M; Nasiri M; Bliss S; McNutt LA; Lazariu V; Miller C
AIDS Patient Care STDS; 2014 Oct; 28(10):513-6. PubMed ID: 25093994
[No Abstract] [Full Text] [Related]
30. [The paradox of fatty diet on protease inhibitors against C hepatitis].
Vida Pérez L
Gastroenterol Hepatol; 2013 Oct; 36(8):549-50. PubMed ID: 23809310
[No Abstract] [Full Text] [Related]
31. Hepatitis C infection: Updates on treatment guidelines.
Pozza R; Hill C; Hefner AM; Vawter B; Hassanein T
Nurse Pract; 2017 May; 42(5):14-23. PubMed ID: 28379888
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of chronic hepatitis C with protease inhibitors: dawn of a new era].
Keeffe EB
Eksp Klin Gastroenterol; 2010; (11):111-3. PubMed ID: 21485527
[No Abstract] [Full Text] [Related]
33. Protease inhibitor-based therapy for hepatitis C virus infection-why wait?
Galati JS
Gastroenterol Hepatol (N Y); 2012 Oct; 8(10):674-6. PubMed ID: 24683375
[No Abstract] [Full Text] [Related]
34. Use of Nonspecific Protease Inhibitors in Research: An Underestimated Problem.
De Hert E; De Meester I
J Am Coll Cardiol; 2021 Aug; 78(5):542-543. PubMed ID: 34325847
[No Abstract] [Full Text] [Related]
35. Hepatitis C virus protease inhibitors: patent highlight.
Abdel-Magid AF
ACS Med Chem Lett; 2012 Sep; 3(9):699-700. PubMed ID: 24900535
[No Abstract] [Full Text] [Related]
36. Management of patients who are not candidates for protease inhibitor therapy.
Pockros PJ
Gastroenterol Hepatol (N Y); 2012 Jul; 8(7):464-6. PubMed ID: 23293556
[No Abstract] [Full Text] [Related]
37. Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization.
Capuozzo M; Ottaiano A; Nava E; Scotti V; Cascone S; Vercellone A; Cinque C; Iaffaioli RV
Front Pharmacol; 2013; 4():114. PubMed ID: 24062687
[No Abstract] [Full Text] [Related]
38. Trends in hepatitis C virus infection therapy: protease inhibitors a step forward in the era of direct acting antivirals.
Popescu C; Gliga S; Aramă V
Rom J Intern Med; 2012; 50(2):117-27. PubMed ID: 23326955
[TBL] [Abstract][Full Text] [Related]
39. Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
Klibanov OM; Vickery SB; Olin JL; Smith LS; Williams SH
Pharmacotherapy; 2012 Feb; 32(2):173-90. PubMed ID: 22392426
[TBL] [Abstract][Full Text] [Related]
40. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
Venkatraman S
Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
